TX 397

Drug Profile

TX 397

Latest Information Update: 21 Aug 2007

Price : $50

At a glance

  • Originator Theramex SAM
  • Class Antineoplastics
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Endometriosis; Prostate cancer

Most Recent Events

  • 20 Dec 1999 Théramex SAM acquired by Merck KGaA
  • 21 May 1998 Preclinical development for Breast cancer in Europe (Unknown route)
  • 21 May 1998 Preclinical development for Endometriosis in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top